Sunday, June 26, 2022

Taking a Closer Look At Bolt Biotherapeutics Inc. (BOLT) Following Its Recent Trade

In a filing, Bolt Biotherapeutics Inc. revealed its Chief Financial Officer Quinn William P. acquired Company’s shares for reported $23575.0 on Dec 08. In the deal valued at $4.71 per share,5,000 shares were bought. As a result of this transaction, Quinn William P. now holds 20,154 shares worth roughly $ 38292.6.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.


Then, Quinn William P. bought 35 shares, generating $162 in total proceeds. Upon buying the shares at $4.64, the Chief Financial Officer now owns 15,154 shares.

Before that, Perez Edith A. bought 411 shares. Bolt Biotherapeutics Inc. shares valued at $1,907 were divested by the Chief Medical Officer at a price of $4.64 per share. As a result of the transaction, Perez Edith A. now holds 1,328 shares, worth roughly $2523.2.

Taking this into account, Morgan Stanley downgraded its Bolt Biotherapeutics Inc. [BOLT] rating to an Equal-weight from a an Overweight in a research note published on Tuesday. A number of analysts have revised their coverage, including SVB Leerink’s analysts, who began to cover the stock in early March with a ‘”an Outperform”‘ rating. Stifel began covering BOLT with a “Buy” recommendation on March 02, 2021. Morgan Stanley started covering the stock on March 02, 2021. It rated BOLT as “an Overweight”.

Price Performance Review of BOLT

On Tuesday, Bolt Biotherapeutics Inc. [NASDAQ:BOLT] saw its stock jump 6.15% to $1.90. On the same session, the stock had its day’s lowest price of $1.79, but rose to a high of $1.96. Over the last five days, the stock has lost -3.06%. Bolt Biotherapeutics Inc. shares have fallen nearly -61.22% since the year began. Nevertheless, the stocks have fallen -88.13% over the past one year. While a 52-week high of $19.28 was reached on 01/03/22, a 52-week low of $1.39 was recorded on 05/09/22. SMA at 50 days reached $1.8424, while 200 days put it at $6.0430. A total of 0.92 million shares were traded, compared to the trading of 0.23 million shares in the previous session.

Levels Of Support And Resistance For BOLT Stock

The 24-hour chart illustrates a support level at 1.8067, which if violated will result in even more drops to 1.7133. On the upside, there is a resistance level at 1.9767. A further resistance level may holdings at 2.0533. The Relative Strength Index (RSI) on the 14-day chart is 51.67, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.1001, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 69.62%. Stochastics %K at 21.79% indicates the stock is a holding.

How much short interest is there in Bolt Biotherapeutics Inc.?

A steep rise in short interest was recorded in Bolt Biotherapeutics Inc. stocks on Apr 28, 2022, growing by 0.37 million shares to a total of 1.62 million shares. Yahoo Finance data shows the prior-month short interest on Mar 30, 2022 was 1.25 million shares. There was a rise of 22.84%, which implies that there is a positive sentiment for the stock. In spite of short shares comprising just 6.45% of the overall stock float, the days-to-cover ratio (short ratio) rose to 7.81.

Bolt Biotherapeutics Inc. [BOLT] – Who Are The Largest Shareholders?

In filings from Citadel Advisors LLC, it is revealed that the company now owns 2,752,156 shares, or roughly 7.35% of the outstanding BOLT shares. In other words, the investor’s shares have fallen by -60,203 from its previous 13-F filing of 2812359.0. Additionally, Suvretta Capital Management LLC decreased 0.00% of its stake after which the total value it holdings stand at $3,791,425, while BlackRock Fund Advisors reduced -2.05% of its stake to hold $2.41 million in the firm. Over the last quarter, Holocene Advisors, LP sold -101,862 shares of Bolt Biotherapeutics Inc., while Eventide Asset Management LLC sold -589,668 shares. At present, The Vanguard Group, Inc. is holding 825,887 shares valued at $1.4 million. Stanford Management Co. owned 719,546 shares of the company at the time of its most recent 13F filing, worth $1.22 million.

However, 5 analysts have rated BOLT stock as a Buy in their predictions for 2022. The most recent change occurred on March 02, 2021 when Guggenheim began covering the stock and recommended ‘”a Buy”‘ rating along with a $42 price target.

Latest news

Related news


Please enter your comment!
Please enter your name here




Download Free eBook For

The 5 Best Growth Stocks 2022

100% free. stop anytime no spam